Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in InventoryChange in ReceivablesChange in Working CapitalDeferred TaxesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet Equity Issued and RepurchasedNet Income
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Sanofi (SNY) over the last 17 years, with Q4 2025 value amounting to -$2.6 billion.

  • Sanofi's Asset Writedowns and Impairment fell 45612.55% to -$2.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$3.1 billion, marking a year-over-year decrease of 106474.63%. This contributed to the annual value of -$2.5 billion for FY2025, which is 84350.65% down from last year.
  • As of Q4 2025, Sanofi's Asset Writedowns and Impairment stood at -$2.6 billion, which was down 45612.55% from -$266.5 million recorded in Q3 2025.
  • In the past 5 years, Sanofi's Asset Writedowns and Impairment ranged from a high of $463.2 million in Q4 2022 and a low of -$2.6 billion during Q4 2025
  • Moreover, its 5-year median value for Asset Writedowns and Impairment was -$87.5 million (2022), whereas its average is -$317.1 million.
  • The largest annual percentage gain for Sanofi's Asset Writedowns and Impairment in the last 5 years was 31088.47% (2022), contrasted with its biggest fall of 13570079.83% (2022).
  • Sanofi's Asset Writedowns and Impairment (Quarter) stood at -$219.6 million in 2021, then skyrocketed by 310.88% to $463.2 million in 2022, then tumbled by 308.13% to -$964.0 million in 2023, then soared by 51.34% to -$469.1 million in 2024, then tumbled by 456.13% to -$2.6 billion in 2025.
  • Its Asset Writedowns and Impairment stands at -$2.6 billion for Q4 2025, versus -$266.5 million for Q3 2025 and -$209.4 million for Q2 2025.